CanImGuide Therapeutics AB, a private biopharmaceutical company based in Lund, Sweden, developing immunology therapeutics, announces that the clinical development of P28R, the company’s lead cancer drug, the first in a new class of immune-modulating drugs, has been initiated in Lund.
CanImGuide has reached a significant milestone by initiating clinical development with P28R, by starting a first-in-man clinical Phase I study in head and neck cancer patients at Skåne University Hospital, Lund, Sweden. In this study, a maximum of 15 patients will be treated by a single intra-tumoral injection of P28R.
CanImGuide is preparing for further clinical development of P28R next year, with the initiation of a clinical phase I/IIa study with subcutaneous administration, also that in head and neck cancer patients. The choice of head and neck cancer specifically only has to do with patient accessibility, says Johan Drott, CEO of CanImGuide. We believe that the immune defense restoration effect of P28R is a mechanism that could contribute to fighting many different types of cancer, and possibly other non-cancer conditions as well, and later clinical development of P28R will certainly have a broader indication target.
The company’s lead drug P28R works through a restoring of the immune system penetration of the tumor that is blocked by tumor cell metabolism of albumin, creating an albumin metabolite that antagonizes the LFA-1 receptors of immune cells and deactivates them. P28R blocks the albumin metabolite from attaching itself to the LFA-1 receptor, and as such it blocks the antagonist from deactivating the immune system, which is what is preventing it from attacking the tumor cells.
As such, P28R has the chance of becoming the first drug in a new class of immunotherapy – LFA-1 antagonist blockers. P28R has already shown significant antitumor effects in mice and dogs.
CanImGuide is currently re-financing in order to fund further pre-clinical and clinical development in 2019. It will eventually seek the partnership of a larger pharmaceutical company for late stage clinical development and commercialization.
For more information on this, please contact:
CEO Johan Drott
+46 70 922 41 40
(email@example.com / www.canimguide.com)
Lund, 11 October 2018
CanImGuide Therapeutics AB , The Board of Directors